The Global Ragweed Pollen Allergy Treatment Market Is Estimated To Be Valued At USD 836.9 Million By 2022 And Is Projected To Register A CAGR Of 4.6% During The Forecast Period.

Ragweed Pollen Allergy Treatment Market Overview:

Ragweed is a flowering plant of the genus Ragweed in the family Asteraceae. Ragweed pollen can cause allergy symptoms in many people. Ragweed pollen season typically hits the U.S. Midwest in early to mid-August and lasts until late September or when temperatures drop significantly.

A ragweed allergy occurs when the immune system mounts an inappropriate response to ragweed pollen. Normally, the immune system promotes chemical changes in the body that help fight off harmful invaders such as viruses and bacteria. However, in people allergic to ragweed, the immune system mistakenly identifies the harmless pollen as a dangerous invader and begins to fight it.

Ragweed pollen is considered one of the most common causes of seasonal allergies, especially in the United States. The pollen present in the ragweed plant is the main cause of this disease. These plants occur in 17 different types of species in North America. People affected by a ragweed allergy develop an autoimmune reaction. Immune cells in affected patients produce chemicals to fight the pollen, viewing it as foreign. This reaction can lead to a variety of irritating symptoms, such as itchy eyes, runny nose, and sneezing. However, these symptoms or allergies can be treated with allergy shots and medications.

Ragweed Pollen Allergy Treatment market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (million USD), with historical and forecast data for the period 2017 to 2030, with 2022 being considered as the base year. This report segments the global Ragweed Pollen Allergy Treatment market in detail. Regional market sizes related to products by type, by application, and by the player are also delivered. In estimating the size of the market, we took into account the impact of COVID-19 and the Russian-Ukraine war.

Key Market Updates:

• In September 2018, Genentech's Xolair received FDA approval for the treatment of allergies. Xolair is the only product biologically approved for the treatment of allergic asthma and chronic idiopathic urticaria. This product is approved for the treatment of allergic asthma in patients 12 years of age and older. According to Genentech, this approval will help address an unmet need for patients and caregivers or parents.

Major Segments Covered in the Global Ragweed Pollen Allergy Treatment Market:

Market Key Players:
ALK-Abello A/S, ASIT Biotech SA, Anergis SA, Biomay AG, Astellas Pharma Inc., Thermo Fisher Scientific Inc, Siemens Healthcare Private Limited, Omega Diagnostics Group PLC, Stallergenes Greer, bioMerieux SA, Lincoln Diagnostics, Inc, HOB Biotech Group Corp Ltd, HYCOR Biomedical, Inc, Alcon, Hitachi Chemical Diagnostics, Inc, Quest Diagnostics Incorporated, Circassia, Immunomic Therapeutics, Inc, Novartis AG, Japan Tobacco Inc, GlaxoSmithKline plc, REGiMMUNE Co, Ltd, Sanofi, and Merck KGaA, and Others.

Ragweed Pollen Allergy Treatment market by Drug Class:

• Antihistamines
• Loratadine
• Diphenhydramine
• Decongestants
• Nasal Corticosteroids
• Others

Ragweed Pollen Allergy Treatment market by Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Channel

Ragweed Pollen Allergy Treatment Market by Regions:

The report estimates revenue growth at the worldwide, regional, and country levels and delivers an analysis of the recent industry trends in each sub-segment from 2017 to 2030. In terms of region, the global ragweed pollen allergy treatment market can be segmented into North America, Europe, Asia Pacific, and the rest of the world. North America is expected to dominate the global market during the forecast period.

North America is expected to account for a large share of the global market due to the high incidence of ragweed allergy. According to the Asthma and Allergy Foundation of America, approximately 23 million people in the U.S. develop ragweed pollen allergies each year. Europe is expected to account for a sizeable market share in terms of revenue during the forecast period owing to the rising patient population and rising adoption of treatments. In Europe, ragweed is most commonly found in northern Italy and southern France, and according to Nature Climate Change, ragweed may be found in Germany, the United Kingdom, and northern Europe in the coming years.

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Significant Market Dynamics:

An increasing number of clinical trials and the development of new treatments are the major factors driving the growth of the global ragweed pollen allergy treatment market. Furthermore, increasing pollution and changing environmental conditions are other factors driving the growth of the market. For example, in 2018, about 75 percent of people who were allergic to pollen were also allergic to ragweed, according to the Asthma and Allergy Foundation of America (AAFA). People who are allergic to one type of pollen tend to be allergic to other types of pollen as well.

Furthermore, an increasing number of approvals for ragweed pollen allergy treatments is expected to drive the overall market growth. For example, Novartis received US FDA approval for Xolair in September 2018 for the treatment of mild to severe persistent hay fever. Since Xolair was first approved, more than 330,000 Americans age 12 and older have been treated for hay fever and asthma.

However, lack of awareness about allergy immunotherapy (AIT) and high cost of treatment are some of the major factors restraining the growth of the global ragweed pollen allergy treatment market.

Report Scope of Global Ragweed Pollen Allergy Treatment Market:

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the Market such as Market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years of data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, region, type, application and etc., and custom research can be added according to specific requirements.
• The report contains a SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Frequently Asked Questions-

What is the CAGR of the Ragweed Pollen Allergy Treatment market?

The Ragweed Pollen Allergy Treatment Market is growing at a CAGR of 4.6% During the Forecast Period.

 What are the key types and applications of the Ragweed Pollen Allergy Treatment market?

- Antihistamines (Loratadine, Diphenhydramine), Decongestants, Nasal Corticosteroids, Others

- Hospital Pharmacy, Retail Pharmacy, Online Channel

Who are the key players in Ragweed Pollen Allergy Treatment market?

ALK-Abello A/S, ASIT Biotech SA, Anergis SA, Biomay AG, Astellas Pharma Inc., Thermo Fisher Scientific Inc, Siemens Healthcare Private Limited, Omega Diagnostics Group PLC, Stallergenes Greer, bioMerieux SA, Lincoln Diagnostics, Inc, HOB Biotech Group Corp Ltd, HYCOR Biomedical, Inc, Alcon, Hitachi Chemical Diagnostics, Inc, Quest Diagnostics Incorporated, Circassia, Immunomic Therapeutics, Inc, Novartis AG, Japan Tobacco Inc, GlaxoSmithKline plc, REGiMMUNE Co, Ltd, Sanofi, and Merck KGaA, and Others.

Any special requirements about this report, please let us know and we can provide a custom report.

Note – In order to provide a more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19 and the Russia-Ukraine war.